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Research Question 
Does 
Bupropion(Wellbutrin)affect 
mood, motivation and risk 
taking in a Tetrabenazine 
model of Depression?
The Present study
● In this study I will be testing to see if this drug 
increases risk taking behavior and suicidality in a 
rodent model of depression
● This increase in risk taking behavior may play a factor 
as to why people harm themselves while being treated 
with the drug
Depression
● Depression is a mood disorder 
that results in reduced 
amounts of dopamine, 
serotonin, and norepinephrine 
in the brain
● Depression can cause 
negative affect symptoms 
(perceiving the world 
negatively as well as loss of 
positive affect symptoms 
(inability to feel reward and 
positive emotion)
Bupropion background
● Bupropion is an 
antidepressant used to treat 
Depression
● Commonly knows as 
Wellbutrin 
● Inhibits the reuptake of 
Dopamine and 
Norepinephrine
● Users feel increased 
motivation, effort, energy, 
and mood.
Bupropion’s relationship with 
suicide
Kriikku, 2016
Suicide was more common among 
people who took Bupropion than people 
who took any other antidepressant
Grunebaum, 2012
Bupropion was worse at relieving 
suicidal behavior and thoughts 
compared to SSRI’s, it also increased 
suicidal behavior.
Hypothesis
● I believe that a depressed rat being treated with Bupropion 
will show increased suicidality, mood and risk taking behavior 
compared to rats who are not using.
● Bupropion increases motivation and increases sensitivity to 
rewards but does not impact obsessions, compulsion, guilt 
and irritability.
● Self-harm produces dopamine and can become an addiction, 
therefore if someone who is using Bupropion partakes in self 
harm than they would feel more dopamine than usual which 
would reinforce them to continue that risky behavior, this can 
eventually lead to suicide
Operational Definitions ● Depression = .75 mg/kg of Tetrabenazine
● Bupropion = 17 mg/kg 
● Mood
○ Will be measured through a social interaction task
● Motivation
○ Will be measured through the splash test
● Risk Taking
○ Will be measured through a Lever pressing task in 
an Operant Box
● Suicidality
○ Will be measured through aggression and 
impulsivivty
Design
4 groups:
● Group Tetrabenazine
● Group Bupropion
● Group Tetrabenazine + Bupropion
● Control Group
Behavioral tasks
● Risk Taking paradigm
○ Rat is placed in an operant box and must choose between a 
small reward with no risk of punishment or a large reward that 
contains a large risk of punishment
● The Social Interaction Test
○ Rat is placed in an arena with another rat. Variables measured 
are social behavior and aggression
● Open Field Test
○ Rats are placed in an arena, this will be used to test impulsivity
● The Splash Test
○ This will be used to assess motivation
Procedure
1. Rats will be trained on how to 
lever press and will be taught the 
Risk taking task
2. Rats will be injected with 
respective drug 
3. They will first undergo the risk 
taking task
4. A week later they will receive 
another dosing of the drug and 
will undergo all other behavioral 
tasks
Expected Results
Expected Results
Expected Results
Discussion  
● Does Bupropion affect suicidal behavior?
○ Yes, this drug could cause people to be suicidal because it increases 
motivation and effort but does not treat guilt irritability, and mood. 
Someone who has high motivation and effort but a poor perception of 
themselves and of the world may be more likely to harm themselves
● Does Bupropion Increase Risk Taking behavior?
○ Yes, this drug increases motivation and causes more dopamine to be 
released which causes people to be more heavily reinforced after 
performing a risky action.
Discussion  
● How does Risk-Taking behavior increase Suicide?
○ When a user performs a risky behavior such as self-harm while 
being treated with Bupropion they may be reinforced more 
heavily because their dopaminergic pathways are reinforcing 
them. Which may cause them to continue to produce that risky 
behavior. This eventually leads them to harming themselves more 
intensely and dangerously which can lead to suicide. This may be 
a reason as to why people harm themselves more frequently while 
being treated with Bupropion.
Limitations 
• I’m using rats not humans, findings can not generalize
• I am injecting the drug but it is typically taken orally
Future directions 
● Testing risk taking behavior in humans 
● Testing risk taking behavior for other antidepressants
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